Jazz Pharmaceuticals

Jazz Pharmaceuticals plc
Public
Traded as NASDAQ: JAZZ
Industry Biotechnology
Pharmaceutical
Predecessor Jazz Pharmaceuticals, Inc.
Azur Pharma plc
Founded March 2005 (2005-03) in Dublin, Ireland
Headquarters Dublin, Ireland
Area served
 Worldwide
Key people
 Bruce C. Cozadd, Chairman & CEO
Products Pharmaceutical drugs
Brands
Revenue Increase US$1.618 billion (2017)[1]
Decrease US$528.8 million (2017)[1]
Increase US$487.8 million (2017)[1]
Total assets Increase US$5.123 billion (2017)[1]
Total equity Increase US$2.713 billion (2017)[1]
Number of employees
 ~1,210 (February 2018)[1]
Website www.jazzpharma.com

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1]

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]

Company history & Acquisitions

2010

On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia[5] In the following December, a new patent was issued for Sodium Oxybate [6]

2011

On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge[7]

2012

On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments[8] In September the company successfully sold its Women's Health business to Meda for $95 million [9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia [10]

2014

In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion[11][12]

2016

In May, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14]

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Jazz Pharmaceuticals

 

 

 

(Merged 2011)

 

 

Jazz Pharmaceuticals

 
 

Azur Pharma PLC

 
 
 
 

 

EUSA Pharma
(Acq 2012)

 
 
 
 

 

Gentium SpA
(Acq 2014)

 
 
 
 

 

Alizé Pharma II
(Acq 2016)

 
 
 
 

 

Celator Pharmaceuticals
(Acq 2016)

 
 
 

References

  1. 1 2 3 4 5 6 7 "Jazz Pharmaceuticals PLC 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. February 2018.
  2. ↑ "History". Jazz Pharmaceuticals. Retrieved 22 November 2016.
  3. ↑ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation".
  4. ↑ http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals
  5. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  6. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  7. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  8. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  9. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  10. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  11. ↑ Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
  12. ↑ "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News (paper)|format= requires |url= (help). 34 (2). January 15, 2014. p. 10.
  13. ↑ "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
  14. ↑ "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.